Stryker (NYSE:SYK) announced its quarterly earnings data on Thursday. The medical technology company reported $0.64 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.62 by $0.02, MarketWatch Earnings reports. Stryker had a net margin of 11.38% and a return on equity of 20.53%. The company had revenue of $2.76 billion for the quarter, compared to the consensus estimate of $2.63 billion.
NYSE SYK opened at $193.30 on Friday. Stryker has a 12 month low of $124.54 and a 12 month high of $226.30. The stock has a market cap of $72.45 billion, a price-to-earnings ratio of 28.10, a PEG ratio of 3.36 and a beta of 0.84. The company’s 50 day moving average is $186.61 and its two-hundred day moving average is $189.31. The company has a current ratio of 2.58, a quick ratio of 1.77 and a debt-to-equity ratio of 0.72.
The company also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be paid a dividend of $0.575 per share. This represents a $2.30 dividend on an annualized basis and a yield of 1.19%. The ex-dividend date is Tuesday, September 29th. Stryker’s payout ratio is 27.85%.
In other Stryker news, CFO Glenn S. Boehnlein sold 10,351 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $185.24, for a total transaction of $1,917,419.24. Following the sale, the chief financial officer now owns 16,321 shares in the company, valued at approximately $3,023,302.04. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Srikant M. Datar sold 200 shares of the firm’s stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $194.32, for a total transaction of $38,864.00. Following the sale, the director now owns 17,686 shares in the company, valued at approximately $3,436,743.52. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 30,670 shares of company stock worth $5,775,251. 6.80% of the stock is owned by company insiders.
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.
See Also: What is Green Investing?
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.